You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The investment bank said CareDx's products are gaining traction and that the stock is positioned for 20 percent to 30 percent growth over the next few years.
The investment bank gave shares of the Temple City, California-based genetic testing company a buy rating and a $20 price target.
Celcuity's companion diagnostic platform CELsignia identifies cellular signals corresponding to drug response using a patient's living tumor cells.
The plan involves expanding testing to 30 million per week, expanding contact tracing, and creating a digital platform to track COVID statuses, among other things.
The investment bank said the company's molecular diagnostics have the potential to replace microarrays for cytogenetics analysis.
The investment bank said that Exact's Cologuard test continues to gain market share, and that its alternatives are largely invasive and inferior.
BTIG gave Centogene a Buy rating, while SVB Leerink and Evercore ISI each gave the company an Outperform rating.
The investment banks cited the company's access to proprietary technology and the potential $5 billion market for Exagen's testing options as reasons for its Outperform rating.
The study said that Cologuard was an "inefficient screening option" for colorectal cancer given its cost as compared to other CRC screening methods.
Cowen and William Blair initiated coverage of Adaptive with Outperform ratings, while JP Morgan assigned an Overweight rating and a $45 price target to the firm's stock.